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Abstract
Background: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing
pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants
exhibiting dual reuptake inhibition of both serotonin (5-HT) and norepinephrine (NE) may achieve higher
rates of remission compared with those acting upon a single neurotransmitter. In this study, the safety and
efficacy of duloxetine, a potent dual reuptake inhibitor of 5-HT and NE, were examined.
Methods: Patients (N = 533) meeting DSM-IV criteria for MDD received open-label duloxetine (60 mg
once a day [QD]) for 12 weeks during the initial phase of a relapse prevention trial. Patients were required
to have a 17-item Hamilton Rating Scale for Depression (HAMD17) total score ≥18 and a Clinical Global
Impression of Severity (CGI-S) score ≥4 at baseline. Efficacy measures included the HAMD17 total score,
HAMD17 subscales, the CGI-S, the Patient Global Impression of Improvement (PGI-I) scale, Visual Analog
Scales (VAS) for pain, and the Symptom Questionnaire, Somatic Subscale (SQ-SS). Quality of life was
assessed using the Sheehan Disability Scale (SDS) and the Quality of Life in Depression Scale (QLDS).
Safety was evaluated by recording spontaneously-reported treatment-emergent adverse events, changes
in vital signs and laboratory analytes, and the Patient Global Impression of Sexual Function (PGI-SF) scale.
Results: The rate of discontinuation due to adverse events was 11.3%. Treatment-emergent adverse
events reported by ≥10% duloxetine-treated patients were nausea, headache, dry mouth, somnolence,
insomnia, and dizziness. Following 12 weeks of open-label duloxetine therapy, significant improvements
were observed in all assessed efficacy and quality of life measures. In assessments of depression severity
(HAMD17, CGI-S) the magnitude of symptom improvement continued to increase at each study visit, while
for painful physical symptoms the onset of improvement was rapid and reached a maximum after 2 to 3
weeks of treatment.
Conclusion: In this open-label phase of a relapse prevention study, duloxetine (60 mg QD) was shown
to be safe and effective in the treatment of MDD.
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Background
Major depressive disorder (MDD) represents one of the
most serious challenges faced by healthcare providers
throughout the world, affecting some 18 million people
in the United States and 340 million people globally [1].
The negative impact of MDD upon patient well-being and
functioning is comparable to that of major chronic medi-
cal conditions such as diabetes, hypertension, coronary
artery disease, and arthritis [2]. Given the enormous
impact of depression upon both the individual patient
and the healthcare system as a whole, the need for effec-
tive treatment is clear.
Antidepressant medications, in particular the selective
serotonin reuptake inhibitors (SSRIs), currently represent
the first line of treatment for MDD. SSRIs attained clinical
acceptance over tricyclic antidepressants (TCAs) in part
due to their improved tolerability profile, including lower
rates of anticholinergic events, orthostatic hypotension,
sedation, and lower toxicity in overdose [3,4]. However,
SSRIs have not demonstrated superior efficacy when com-
pared with TCAs [5], and up to half of all depressed
patients fail to respond to SSRI therapy [6]. Thus, the need
for alternative safe and effective treatments for MDD is
clear.
The antidepressant duloxetine is a potent dual reuptake
inhibitor of serotonin (5-HT) and norepinephrine (NE)
[7], but lacks significant affinity for muscarinic, histamin-
ergic, α-adrenergic, dopaminergic, serotonergic, and opi-
oid receptors [8]. Previous double-blind, placebo-
controlled studies have established the safety and efficacy
of duloxetine in the treatment of MDD [9-14]. For licens-
ing purposes, the European Committee for Proprietary
Medicinal Products (CPMP) requires that an antidepres-
sant's short-term effect be maintained for a longer dura-
tion. For this reason, a randomized withdrawal study, also
called a relapse prevention study, was considered the best
design. The study included an initial 12-week, open-label
treatment phase followed by a 26-week, double-blind,
randomized withdrawal phase. The primary results of the
relapse prevention study have been published elsewhere
[15]. Here we present results from the initial open-label
acute phase of a relapse prevention study, in which a
cohort of over 500 patients received duloxetine (60 mg
once-daily) for 12 weeks.
Methods
Study design
This was an open-label study conducted at 29 sites in the
United States, France, Italy and Spain. Patients meeting
entry criteria received duloxetine 60 mg once-daily for 12
weeks. Study visits were scheduled after 1, 2, 4, 7, 10 and
12 weeks of treatment. Study drug consisted of 2 capsules
(30 mg of duloxetine in each capsule) taken once-daily. If
necessary due to tolerability, the dose could be reduced to
1 capsule (duloxetine 30 mg/d) at any point during the
first 4 weeks of treatment. Patients had to return to 2 cap-
sules once-daily after Week 4 or they were discontinued
from the study.
Concomitant medications with primarily central nervous
system activity were not allowed, with the exception of
benzodiazepines (e.g. lorazepam, diazepam, chlo-
rdiazepoxide) and certain hypnotics (chloral hydrate) for
a maximum of 6 total days (intermittent or consecutive)
during the 12-week period. Use of non-prescription, over-
the-counter pain medications (e.g. paracetamol, acetami-
nophen, ibuprofen) was allowed. Narcotic use was
allowed only upon approval by a study physician. Use of
certain prescription medications such as ACE inhibitors,
antiarrhythmics, or beta-blockers was permitted provided
the patient had been on a stable dose for a minimum of 3
months prior to study enrollment.
In accordance with the principles of the Declaration of
Helsinki, all patients gave informed consent prior to
administration of any study drug or study procedures. The
study protocol was approved by both central and local
ethical review boards (ERBs) in the 4 countries in which
the study was conducted. The participating ERBs included
the following: Schulmann and Associates Institutional
Review Board (16 sites), Hospital Tarnier Paris-Cochin (4
sites), Policlinico Universitario Udine, Azienda Ospe-
daliera S. Giovanni Battista, Universita' Di Parma Comi-
tato Etico, Hospital General Yague, Hospital Clinico De
Salamanca, Hospital Universitario Nuestra Senora De
Valme, Institut Munincipal Assistencia Sanitaria, Hospital
General De Vic, and McLean Hospital.
Selection of patients
All patients met diagnostic criteria for MDD as defined in
the Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition (DSM-IV) [16]. The diagnosis of MDD was con-
firmed by the Mini International Neuropsychiatric Inter-
view (MINI) [17]. Baseline disease severity was defined by
patients' scores on the 17-item Hamilton Rating Scale for
Depression (HAMD17) [18], and the Clinical Global
Impression of Severity (CGI-S) scale [19]. To be eligible
for the study, patients were required to have a HAMD17
total score ≥ 18 and a CGI-S score ≥ 4 at two consecutive
screening visits.
Study participants were adult outpatients at least 18 years
of age, and were recruited from several sources including
psychiatric health care centers and TV/radio/print adver-
tisements. Patients were excluded for the following rea-
sons: a current and primary Axis I disorder other than
MDD, including but not limited to dysthymia; the pres-
ence of an Axis II disorder that could interfere with com-BMC Psychiatry 2007, 7:43 http://www.biomedcentral.com/1471-244X/7/43
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pliance with the study protocol; any previous diagnosis of
bipolar disorder, schizophrenia, or other psychotic disor-
ders; any anxiety disorder as a primary diagnosis within
the past year; serious suicidal risk; lack of response of the
current depressive episode to two or more adequate
courses of antidepressant therapy at a clinically appropri-
ate dose for a minimum of 4 weeks, or treatment resistant
depression; serious medical illness (including any cardio-
vascular, hepatic, respiratory, hematologic, endocrino-
logic, renal, or neurologic disease, or clinically significant
laboratory abnormality); initiating or stopping psycho-
therapy within six weeks prior to enrollment; a DSM-IV-
defined history of substance abuse or dependence within
the past year; a positive urine drug screen for any sub-
stance of abuse.
Safety assessments
Safety measures recorded at every visit included spontane-
ously reported treatment-emergent adverse events, supine
blood pressure (BP), and heart rate (HR). Elevated blood
pressure was defined as supine systolic BP ≥ 140 mm Hg
and at least 10 mm Hg greater than baseline, or supine
diastolic BP ≥ 90 mm Hg and at least 10 mm Hg greater
than baseline. These definitions for elevated blood pres-
sure were based on diagnostic criteria from the Joint
National Committee (JNC) on prevention, detection,
evaluation, and treatment of high blood pressure [20]. A
patient was considered to have a sustained elevation in BP
if criteria for elevated systolic or diastolic BP were met at
3 consecutive visits. Potentially clinically significant
(PCS) high BP values were defined as: systolic BP ≥ 180
mm Hg and an increase ≥20 mm Hg from baseline, or
diastolic BP ≥ 105 mm Hg and an increase ≥15 mm Hg
from baseline. A treatment-emergent elevated HR was
defined as a value ≥100 bpm with an increase ≥10 bpm
from baseline, while a PCS elevated HR was defined as
≥120 bpm and an increase ≥15 bpm from baseline. Crite-
ria used for PCS values for blood pressure and heart rate
were developed for previous duloxetine registration stud-
ies in conjunction with the FDA's Division of Neurophar-
macological Drug Products (DNDP). A PCS value for
Fridericia's correction of the QT interval (QTcF) was
defined as any postbaseline value ≥450 msec for males or
≥470 msec for females with an increase in QTcF of ≥30
msec from baseline. Blood for hematology was collected
at baseline and at the last patient visit (Week 12). Blood
for chemistry laboratories was collected at baseline and at
Weeks 4 and 12. Normal values for laboratory analytes
were based on reference ranges provided by Covance Lab-
oratories, Inc (Princeton, NJ). PCS weight changes were
defined as an increase or decrease of ≥7% from baseline
body weight.
Changes in sexual functioning were assessed by means of
the self-rated Patient Global Impression of Sexual Func-
tion (PGI-SF) scale [21], which was collected at baseline
and at the last study visit. The PGI-SF is a 4-question
instrument that assesses: (i) sexual interest/desire, (ii)
erection (for men) or vaginal lubrication (for women),
(iii) ability to achieve orgasm, and (iv) an overall rating of
sexual function. Each question was rated on a 5-point
scale ranging from 1 (no impairment) to 5 (severely
impaired).
Efficacy measures
Efficacy measures included the HAMD17  total score;
HAMD17 subscales, including anxiety/somatization (sum
of Items 10, 11, 12, 13, 15, and 17), retardation (sum of
Items 1, 7, 8, and 14), sleep (sum of Items 4, 5, and 6),
core (sum of Items 1, 2, 3, 7, and 8), and Maier (sum of
Items 1, 2, 7, 8, 9, and 10); the CGI-S; the Patient Global
Impression of Improvement (PGI-I) scale [19]; Visual
Analog Scales (VAS) for pain [22] (six questions regarding
the experience of overall pain, headache, back pain,
shoulder pain, pain interference with daily activities, and
proportion of the day with pain); the Symptom Question-
naire, Somatic Subscale (SQ-SS) [23]; and the pain sub-
scale of the SQ-SS (sum of Items 5 (no pains anywhere),
8 (tight head or neck), 10 (feeling of pressure in head or
body), 12 (no aches anywhere), 16 (pressure on head), 19
(muscle pains), 21 (headaches), and 23 (head pains)).
Health outcomes were assessed using the Quality of Life
in Depression Scale (QLDS) [24] and the Sheehan Disa-
bility Scale (SDS) [25].
Statistical methods
Safety analyses included data from all patients, while effi-
cacy analyses included patients with a baseline and at least
1 postbaseline observation. All results unless otherwise
noted were obtained from pre-specified analyses, con-
ducted as described in the statistical analysis plan within
the study protocol. The primary outcome of the parent
study was an assessment of maintenance of effect of
duloxetine 60 mg QD compared with placebo by a com-
parison of time to relapse among patients who responded
to open-label duloxetine treatment. Response was defined
as ≥50% decrease in HAMD17 total score from baseline,
while remission was defined as a HAMD17 total score ≤7.
In this single-group, open-label study the changes from
baseline to endpoint were analyzed with a paired t-test
(compared with zero), using the method of last observa-
tion carried forward for subjects who withdrew prema-
turely. The change from baseline to each visit was
analyzed using a mixed-effects model repeated measures
(MMRM) approach [26,27] which included only visit and
investigator as covariates. Response and remission rates
are reported as raw values, and do not control for site var-
iation. For laboratory data, the changes from baseline toBMC Psychiatry 2007, 7:43 http://www.biomedcentral.com/1471-244X/7/43
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endpoint were analyzed using Wilcoxon signed rank test
due to non-normality of the changes.
Within this report, the term "significant" is used to denote
statistical significance (p ≤ .05).
Results
Baseline patient characteristics
A total of 681 patients entered the screening phase of the
study, of whom 148 failed to meet entry criteria. Of the
148 patients who did not meet entry criteria, the majority
(76%) failed to meet the specific protocol entry criteria
(described in the selection of patients section). Other rea-
sons for screen failure included patient decision (17%)
and lost to follow-up (4%).
The remaining 533 patients were enrolled into the 12-
week open-label acute therapy phase at the 29 study sites
(number of patients enrolled at each site: minimum = 2;
maximum = 38; median = 17). Baseline patient demo-
graphics and psychiatric profiles are presented in Table 1.
The median exposure to duloxetine was 81 days, and the
study yielded data from approximately 92 patient-years of
exposure. Concomitant medications used by ≥5% of
patients were ibuprofen, acetaminophen, aspirin,
naproxen sodium, and multivitamins. During the first 4
weeks of the study, 80 of 529 patients who started acute
therapy at a dose of 60 mg QD (15.1%) required a tempo-
rary dose reduction.
Safety
Sixteen patients (3.0%) reported 20 serious adverse events
during the 12 week study period. The events occurring in
more than 1 patient were suicide attempt (3/533, 0.6%)
and suicidal ideation (2/533, 0.4%). One patient died
during the course of the study – death was due to suicide.
The completed suicide occurred in a middle-aged male
after approximately 2 weeks of treatment with duloxetine,
and the principal investigator considered the suicide unre-
lated to the study drug. Other serious adverse events
reported in this study were as follows: unstable angina,
anxiety, appendicitis, atrial fibrillation, cerebrovascular
disorder, chest pain, confusional state, depression, dizzi-
ness, feeling abnormal, necrotizing fascitis, perirectal
abscess, skin laceration, and vaginal hemorrhage.
A total of 60/533 patients (11.3%) discontinued from the
study due to adverse events. The majority of discontinua-
tions (48/60) occurred at the first three study visits – Week
1 (24), Week 2 (7), and Week 4 (17). Adverse events lead-
ing to discontinuation in ≥ 0.5% of patients were nausea
(11/533, 2.1%), somnolence (4/533, 0.8%), suicide
attempt (3/533, 0.6%), and vomiting (3/533, 0.6%).
Other reasons for study discontinuation included patient
decision (11.6%), loss to follow-up (8.1%), protocol vio-
lation (5.1%) and lack of efficacy (1.9%). Treatment-
emergent adverse events reported by ≥5% of patients are
presented in Table 2. The most commonly reported
adverse events were nausea, headache, dry mouth, som-
nolence, insomnia, and dizziness.
A mean baseline-to-endpoint increase in supine HR of 1.7
bpm was observed during the 12 weeks of therapy (T =
3.9, df = 512, p < .001). Mean changes (SD) in supine
systolic and diastolic BP were an increase of 1.4 (12.8)
mm Hg and 0.7 (9.3) mm Hg, respectively (T = 2.4, df =
Table 2: Treatment-emergent adverse events reported by ≥5% of 
patientsa
n (%)
Duloxetine, 60 mg 
QD (N = 533)
Nausea 191 (35.8)
Headache 108 (20.3)
Dry mouth 96 (18.0)
Somnolence 72 (13.5)
Insomnia 56 (10.5)
Dizziness 54 (10.1)
Diarrhea 53 (9.9)
Constipation 42 (7.9)
Increased sweating 37 (6.9)
Anxiety 33 (6.2)
Decreased appetite 33 (6.2)
Tremor 32 (6.0)
Fatigue 31 (5.8)
Vomiting 28 (5.3)
a Incidence is defined as the percentage of subjects reporting a first 
occurrence or worsening of the event during the acute phase of the 
study.
Table 1: Baseline patient demographics and psychiatric profile
Characteristic Duloxetine, 60 mg 
QD (N = 533)
Gender, n (%) 383 (71.9)
Female
Age, mean yrs (SD) 43.4 (12.7)
Age range, yrs 18 – 76
Weight, mean kg (SD) 82.1 (22.3)
Origin, n (%)
African descent 34 (6.4)
Caucasian 479 (89.9)
East/Southeast Asian 2 (0.4)
Hispanic 14 (2.6)
Western Asian 1 (0.2)
Other 3 (0.6)
Psychiatric profile
17-Item Hamilton Rating Scale for 
Depression total score, mean (SD)
23.7 (3.6)
Clinical Global Impression of Severity, 
mean (SD)
4.55 (0.63)BMC Psychiatry 2007, 7:43 http://www.biomedcentral.com/1471-244X/7/43
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512, p = .017, and T = 1.7, df = 512, p = .084, respectively).
The incidence of treatment-emergent sustained elevations
in blood pressure were: systolic BP – 5/513 (1.0%);
diastolic BP – 4/513 (0.8%); either systolic or diastolic BP
– 8/513 (1.6%). No patients had PCS low values for blood
pressure or heart rate. The incidence of PCS high values
were: systolic BP – 1/513 (0.2%); diastolic BP – 4/513
(0.8%); heart rate – 1/513 (0.2%).
Patients had a mean decrease in body weight of -0.1 kg
[SD = 2.4] (T = -0.7, df = 428, p = .50). One patient (0.2%)
experienced a PCS weight loss, while two patients (0.5%)
had a PCS weight gain.
Of the 225 patients having an ECG classified as normal at
baseline and having at least 1 post-baseline measurement,
12.4% (28/225) had a treatment-emergent abnormal
ECG. No patients (0/402) had a treatment-emergent PCS
QTcF interval.
Baseline-to-endpoint mean changes on all 4 items of the
PGI-SF were negative, indicating an improvement in sex-
ual functioning. When analyzed separately by gender
(Table 3), female patients demonstrated significantly
greater improvement compared with male patients on
item 2 (erection/vaginal lubrication), item 3 (ability to
achieve orgasm), and item 4 (overall sexual functioning).
The incidence of spontaneously-reported adverse events
related to sexual functioning was: erectile dysfunction
2.4%, delayed ejaculation 2.3%, decreased libido 2.3%,
anorgasmia 1.7%, abnormal orgasm 1.1%.
Statistically significant mean baseline-to-endpoint
changes were observed in some laboratory analytes (e.g.
gamma glutamyltransferase: mean change -0.69 U/L (SD
= 23.8), Wilcoxon p = .002; alkaline phosphatase: mean
change 1.46 U/L (SD = 10.9), Wilcoxon p = .006). How-
ever, the incidence of treatment-emergent abnormal labo-
ratory values was low. The only analyte with an incidence
of abnormal values ≥10% was high creatine phosphoki-
nase (11.4%). In the case of liver enzymes, the incidence
of alanine transaminase (ALT) and aspartate transaminase
(AST) values greater than or equal to 1, 3, 5, 10, and 20
times the upper limit of normal (ULN) were a priori spec-
ified analyses. During acute-phase treatment, 37/377
patients (9.8%) had ALT values that were greater than 1×,
but less than 3×, the ULN. One patient (0.2%) had an ALT
elevation greater than 3×, but less than 5×, the ULN, while
no patients had ALT values that were ≥5× ULN. In the case
of AST, 37/393 patients (9.4%) had a reading that
exceeded 1×, but did not exceed 3×, the ULN. Two
patients (0.5%) had an AST elevation greater than 3×, but
less than 5×, the ULN, and 1 patient (0.2%) experienced
an AST elevation greater than 5×, but less than 10×, the
ULN. In the 28 patients with normal or low bilirubin at
baseline who then had treatment-emergent abnormal ALT
during acute phase therapy, 1 patient (3.6%) had a corre-
sponding treatment-emergent abnormal high bilirubin
value. The mean baseline-to-endpoint change in total
bilirubin did not achieve statistical significance (0.07
µmol/L (SD = 3.2), Wilcoxon p = .584), while the inci-
dence of abnormal high total bilirubin at anytime was
0.7%. While statistically significant within-group mean
changes were observed for some laboratory values, the
magnitude of these changes was not considered clinically
relevant in light of the small number of treatment-emer-
gent abnormal values. Abnormal values in hepatic
enzymes were usually transient and of low magnitude.
Increases in ALT/AST values were associated with increases
Table 3: PGI-SF – mean change by gender
Gender Baseline, mean 
(SD)
Change, mean 
(SD)
p-valuea Between-gender p-valueb
Item 1 Sexual 
interest/desire
Female (n = 280) 3.57 (1.53) -1.01 (1.62) T = -10.5, df = 279, p < 
.001
F(1, 370) = 0.9, p = .350
Male (n = 119) 3.25 (1.44) -0.71 (1.67) T = -4.7, df = 118, p < .001
Item 2 Erection 
(male); vaginal 
lubrication 
(female)
Female (n = 270) 2.46 (1.56) -0.53 (1.52) T = -5.8, df = 269, p < .001 F(1, 360) = 7.6, p = .006
Male (n = 119) 2.72 (1.46) -0.29 (1.66) T = -1.9, df = 118, p = .055
Item 3 Ability to 
achieve orgasm
Female (n = 267) 3.25 (1.64) -0.74 (1.74) T = -7.0, df = 266, p < .001 F(1, 354) = 4.3, p = .038
Male (n = 116) 2.55 (1.48) 0.14 (1.74) T = 0.9, df = 115, p = .396
Item 4 Overall 
sexual functioning
Female (n = 269) 3.40 (1.59) -0.87 (1.64) T = -8.7, df = 268, p < .001 F(1, 359) = 4.9, p = .027
Male (n = 119) 2.96 (1.50) -0.27 (1.71) T = -1.7, df = 118, p = .089
a within-stratum p-values from paired t-test.
b p-values for gender from ANCOVA with baseline PGI-SF, investigator, and gender in the model.
PGI-SF = Patient Global Impression of Sexual FunctioningBMC Psychiatry 2007, 7:43 http://www.biomedcentral.com/1471-244X/7/43
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in bilirubin in 1 (3.6%) patient, but the finding was not
considered clinically relevant.
Efficacy
All assessed depression efficacy measures (HAMD17, CGI-
S, PGI-I) showed significant improvement following 12
weeks of duloxetine therapy (Table 4). A visitwise plot of
mean change in HAMD17 total score for patients receiving
duloxetine (60 mg QD) is presented in Figure 1.
The rate of response at Week 12 was 67.9% (347/511
patients), while the endpoint remission rate was 52.8%
(270/511 patients; LOCF analyses). Utilizing the entry cri-
teria for the relapse-prevention phase of this study (no
longer meeting DSM-IV criteria for MDD; HAMD17 total
score ≤9; CGI-S score ≤2), 280/533 patients (52.5%) met
the entry criteria.
Analyses of mean change in HAMD17 total score revealed
no significant treatment-by-strata interactions for age
(<55 years vs. ≥55 years), gender, ethnic origin (Caucasian
vs. other), baseline HAMD17 score (<19 vs. ≥19, or <25 vs.
≥25), number of previous major depressive episodes
(<median vs. ≥median), or treatment history (no previous
antidepressants vs. ≥1 previous antidepressant therapy).
Scales assessing the severity of painful physical symptoms
(VAS) and somatic symptoms (SQ-SS) showed significant
improvement following 12 weeks of duloxetine therapy
(Table 5). A visitwise plot of mean changes in the six
assessed VAS pain severity questions is shown in Figure 2.
Both assessments of quality of life (SDS, QLDS) also dem-
onstrated significant improvement from baseline to end-
point (Table 6).
Discussion
The results of the current investigation are based on the
initial 12-week, open-label acute treatment phase of a ran-
domized withdrawal study of duloxetine in the preven-
tion of relapse of MDD. Results of the parent study have
been published and show that patients receiving duloxet-
ine 60 mg/d had significantly longer times to relapse than
patients receiving placebo [15]. The current analysis uti-
lized data from an open-label setting to assess the safety
and efficacy of a once-daily 60 mg duloxetine dose during
acute phase treatment of MDD. Although the study
yielded data from a cohort of over 500 patients receiving
duloxetine at the target therapeutic dose for up to 12
Visitwise plot of mean change in HAMD17 total score for  patients receiving duloxetine (60 mg QD, n = 511) Figure 1
Visitwise plot of mean change in HAMD17 total score for 
patients receiving duloxetine (60 mg QD, n = 511). MMRM 
analysis. * p < .001 from t-test for LS mean change = 0.
Table 4: Summary of efficacy measures
Baseline, mean (SD) Endpoint, mean (SD) p-valuea
Hamilton Rating Scale for Depression total 
score (n = 511)
23.7 (3.6) 9.9 (7.7) T = -39.1, df = 510, p < .001
Hamilton Rating Scale for Depression 
subscales (n = 511)
Core 9.5 (1.7) 3.4 (3.7) T = -37.2, df = 510, p < .001
Maier 12.2 (2.0) 4.5 (4.4) T = -38.1, df = 510, p < .001
Anxiety/Somatization 7.6 (1.9) 3.6 (2.7) T = -30.7, df = 510, p < .001
Retardation 8.2 (1.5) 3.4 (3.1) T = -35.3, df = 510, p < .001
Sleep 3.8 (1.7) 1.7 (1.8) T = -23.5, df = 510, p < .001
Clinical Global Impression of Severity (n = 
512)
4.6 (0.6) 2.3 (1.3) T = -36.1, df = 511, p < .001
Patient Global Impression of Improvement (n 
= 511)
N/A 2.6 (1.4) N/A
LOCF mean change analysis
a p-values are from paired t-test for mean change from baseline to endpoint = 0.BMC Psychiatry 2007, 7:43 http://www.biomedcentral.com/1471-244X/7/43
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weeks, interpretation of results from an open-label study
should be approached cautiously. The absence of placebo
or active comparator treatment arms limits our ability to
draw firm conclusions from the current results, especially
with regard to efficacy outcomes. Patients in an open-
label study will exhibit the combined benefits of both
drug and placebo responses, and therefore efficacy results
such as response and remission rates may be more favora-
ble than those obtained from double-blind, placebo-con-
trolled studies. Furthermore, the statistical significance of
treatment outcomes can only be assessed relative to base-
line values rather than a comparator group. However, an
open-label setting does provide a more realistic approxi-
mation of clinical practice when compared with a double-
blind study, and a large study such as this can yield a sub-
stantial body of safety and tolerability data. In certain
areas, such as rates of discontinuation and the incidence
of spontaneously-reported adverse events, results from an
open-label study may be especially relevant for practicing
clinicians. With these limitations in mind, we discuss in
general terms the principal findings from this study.
Wherever possible, comparisons with data from previous
double-blind, placebo-controlled studies are utilized to
provide context for the current results.
The rate of discontinuation due to adverse events in this
study (11.3%) was similar to that observed in double-
blind, placebo-controlled studies of duloxetine, 60 mg
once-daily (13.8% [9] and 12.5% [10]) and is also
broadly consistent with the reported rates of discontinua-
tion due to adverse events presented in the full prescribing
information for other antidepressants (6% escitalopram
[28], 10% paroxetine controlled release [29], 11% venla-
faxine extended release [30]). Furthermore, the incidence
and pattern of treatment-emergent adverse events was
also consistent with previously published data. In an anal-
ysis of pooled data from placebo-controlled studies of
duloxetine (40–120 mg/d), adverse events occurring in
≥5% of duloxetine-treated patients, and at twice the rate
for placebo, were nausea, dry mouth, fatigue, dizziness,
constipation, somnolence, decreased appetite, and
increased sweating [14]. The incidence of treatment-emer-
gent nausea in the present study (35.8%) was similar to
that reported in 2 placebo-controlled studies of duloxet-
ine 60 mg QD [9,10]. Although patients could request a
reduction of the duloxetine dose from 60 mg QD to 30
Visitwise plot of mean change in VAS pain severity scores for  patients receiving duloxetine (60 mg QD) Figure 2
Visitwise plot of mean change in VAS pain severity scores for 
patients receiving duloxetine (60 mg QD). MMRM analysis. p 
< .001 for each item at all visits (t-test for LS mean change = 
0).
Table 5: Summary of physical symptom efficacy measures
Baseline, mean (SD) Endpoint, mean (SD) p-valuea
VAS pain severity
Overall (n = 504) 33.8 (26.6) 21.3 (25.6) T = -10.5, df = 503 p < .001,
Headache (n = 504) 27.6 (27.8) 15.3 (22.4) T = -9.4, df = 503, p < .001
Back pain (n = 504) 28.7 (29.3) 15.8 (23.3) T = -10.7, df = 503, p < .001
Shoulder pain (n = 501) 23.1 (28.9) 14.1 (23.2) T = -7.7, df = 500, p < .001
Interference with daily activities 
(n = 501)
28.2 (28.2) 17.3 (25.3) T = -8.8, df = 500, p < .001
Time in pain while awake (n = 
500)
38.3 (32.2) 23.3 (28.6) T = -10.3, df = 499, p < .001
Symptom Questionnaire, 
Somatic Subscale (n = 492)
12.4 (5.3) 7.6 (5.1) T = -19.5, df = 491, p < .001
Symptom Questionnaire, 
Somatic Subscale pain items 
(n = 504)
4.9 (2.4) 3.5 (2.6) T = -11.9, df = 503, p < .001
LOCF mean change analysis
ap-values are from paired t-test for mean change from baseline to endpoint = 0
VAS = Visual Analog ScaleBMC Psychiatry 2007, 7:43 http://www.biomedcentral.com/1471-244X/7/43
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mg QD at any point during the first 4 weeks of therapy,
85% of patients tolerated the starting dose of 60 mg QD
without the need for downward titration.
The incidence of spontaneously-reported adverse events
related to sexual functioning was relatively low. However,
spontaneous reports frequently under-represent the actual
incidence of sexual side-effects, and more accurate esti-
mates may be elicited using validated, structured ques-
tionnaires. In the present study, the Patient Global
Impression of Sexual Function (PGI-SF) questionnaire
was utilized to assess treatment-emergent impairment of
sexual functioning. Female patients experienced signifi-
cant within-group mean improvements on all 4 items of
the PGI-SF, while male patients experienced improvement
on Item 1 (sexual interest/desire). While results from an
open-label study should be viewed with a degree of cau-
tion, these results suggest that duloxetine does not have a
substantial adverse impact upon patient's perception of
sexual functioning. By way of comparison, in four double-
blind, placebo- and paroxetine-controlled studies of up to
9 months duration, the Arizona Sexual Experience (ASEX)
scale was utilized to compare the incidence of sexual dys-
function in patients receiving duloxetine with the corre-
sponding rates in paroxetine- and placebo-treated
patients. Results of an analysis of pooled data from these
studies showed that the incidence of acute-phase sexual
dysfunction in patients receiving duloxetine (40–120 mg/
d) was significantly lower than that for patients receiving
paroxetine (20 mg QD) [31].
Consistent with duloxetine's pharmacological profile as a
reuptake inhibitor of NE, a mean increase in heart rate was
observed (1.7 bpm from baseline to endpoint). The mag-
nitude of this increase is similar to that observed in an
analysis of pooled data from acute-phase, placebo-con-
trolled studies of duloxetine (1.4 bpm vs. -0.6 bpm for
placebo) [32]. Modest increases in HR have also been
observed during treatment of depressed patients with the
NE reuptake inhibitor reboxetine (increase in HR of
approximately 8% during 3 weeks of treatment at 4–8 mg/
d) [33] and the 5-HT and NE reuptake inhibitor venlafax-
ine (increase of 3.8 bpm during 8 weeks of treatment at
225 mg/d) [34]. Duloxetine also produced small (less
than 2 mm Hg) mean increases in blood pressure – in the
case of supine systolic BP the mean change to endpoint
(1.4 mm Hg) was statistically but not clinically significant
when compared with the baseline value. These mean
changes are consistent with those observed in acute-
phase, placebo controlled studies of duloxetine (40–120
mg/d) [32]. Thus, in an analysis of pooled data, mean
change in supine systolic BP was 0.8 mm Hg for duloxet-
ine vs. -1.4 mm Hg for placebo (p < .001), while mean
change in supine diastolic BP was 0.9 mm Hg for duloxe-
tine vs. 0.4 mm Hg for placebo (p = .099) [32].
In the present study, duloxetine lacked significant effects
on the QT interval. None of the 402 patients providing
ECG data had a PCS prolongation of corrected QT inter-
val. These data are consistent with results obtained from
placebo-controlled studies of duloxetine, which found no
evidence for prolongation of QTc intervals in duloxetine-
treated patients when compared with those receiving pla-
cebo [32].
During the course of this 12-week study, patients receiving
duloxetine had a small (0.1 kg) decrease in mean body
weight. In the absence of a placebo comparator, no defin-
itive conclusions can be drawn concerning the signifi-
cance of this mean change. However, in an analysis of
pooled data from acute-phase, placebo-controlled trials of
up to 12 weeks duration, patients receiving duloxetine
(40–120 mg/d) exhibited a mean change in weight of -
0.46 kg, compared with 0.23 kg for those receiving pla-
cebo (p < .001) [32]. Furthermore, results from a long-
term (52-week) open-label study of duloxetine (80–120
mg/d) demonstrated that mean body weight decreased
slightly in the first few weeks of treatment, returned to
baseline levels at intermediate visits, and showed an
increase of 1.1 kg at the study endpoint [35].
In a large study with many measures, small clinically
insignificant mean changes in laboratory values com-
monly achieve statistical significance. Thus, in this large
Table 6: Summary of health outcome measures
Baseline, mean (SD) Endpoint, mean (SD) p-valuea
Quality of Life in Depression 
Scale (n = 385)
19.0 (7.7) 8.2 (8.7) T = -22.6, df = 384, p < .001
Sheehan Disability Scale
Total (n = 419) 18.7 (5.6) 9.5 (7.8) T = -22.9, df = 418, p < .001
Work (n = 315) 5.7 (2.5) 3.0 (2.8) T = -15.6, df = 314, p < .001
Social life (n = 419) 6.6 (2.3) 3.3 (2.9) T = -22.1, df = 418, p < .001
Family life (n = 420) 6.3 (2.3) 3.2 (2.8) T = -19.5, df = 419, p < .001
LOCF mean change analysis
ap-values are from paired t-test for mean change from baseline to endpoint = 0BMC Psychiatry 2007, 7:43 http://www.biomedcentral.com/1471-244X/7/43
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study, mean changes in some laboratory values were sta-
tistically significant, but small in magnitude and of doubt-
ful clinical relevance. However, definitive evidence of
non-causality is problematic in the absence of placebo
control. In the present study, the incidence of ALT and
AST values greater than 1×, but less than 3× the ULN, were
9.8% and 9.4%, respectively, while 1 patient (0.2%) had
an ALT elevation greater than 3× the ULN. These results
are consistent with observations from controlled studies
of duloxetine. Within the primary placebo-controlled
database (pooled data from 8 studies), the incidence of
abnormal (high) values for ALT (duloxetine 9.5% vs. pla-
cebo 7.4%; p = .146) and AST (duloxetine 8.1% vs. pla-
cebo 6.0%; p = .122) did not differ significantly from the
placebo rate [32,36]), while elevations of ALT greater than
3× the ULN occurred in 0.9% (8/930) of duloxetine-
treated patients compared with 0.3% (2/652) of those
receiving placebo [36]. Analyses from another long-term
(52-week), open-label clinical study of duloxetine (N =
2109) showed that duloxetine use was associated with a
mild, transient, self-limited rise in ALT and AST, and these
changes did not appear to be of clinical significance
[35,36].
The efficacy of duloxetine (40–120 mg/d) in the acute
treatment of MDD has been established in a number of
acute phase, double-blind, placebo-controlled studies, in
addition to a long-term open-label study [9-14,35]. Effi-
cacy results obtained in this study are consistent with
those obtained previously at a 60 mg once daily dose
[9,10], although double-blind, placebo-controlled studies
should be regarded as the primary source of efficacy data,
with open-label studies such as this playing a supporting
role. The time course of improvement in individual symp-
tom domains is noteworthy. In assessments of depression
severity (HAMD17, CGI-S) the magnitude of improvement
continued to increase at each study visit, while for painful
physical symptoms the onset of improvement was rapid
and reached a maximum after 2 to 3 weeks of treatment.
With regard to duloxetine's effect on overall pain severity
improvement, our observations are consistent with exper-
imental data indicating that both 5-HT and NE exert anal-
gesic effects via descending pain pathways [37-39]. The
effects on painful symptoms observed in this study are
consistent with data from other duloxetine studies dem-
onstrating analgesic effects in depressed patients [40], and
the results from the current study are also supportive of
those obtained previously from double-blind, placebo-
controlled studies which suggest that duloxetine's effect
upon painful physical symptoms is, to some extent, inde-
pendent of its effects upon core emotional symptoms of
depression. Thus, in a path analysis of pooled data from 2
placebo-controlled clinical trials, 50% of duloxetine's
total effect on overall pain severity was found to be inde-
pendent of changes in depressive symptom severity [41].
In the current study, the rate of treatment response (≥50%
reduction in HAMD17  total score from baseline) was
67.9%, while the remission rate (HAMD17 total score ≤7)
was 52.8% (LOCF analysis). In two previously-published
placebo-controlled, 9-week studies of duloxetine (60 mg
once-daily), estimated probabilities of response (MMRM
analysis) were 62% [9] and 65% [10] while probabilities
of remission were 44% [9] and 43% [10]. In other pla-
cebo-controlled studies of duloxetine at doses up to 120
mg/d probabilities of remission (MMRM) of up to 57%
have been observed [14]. The remission rate in the present
study is somewhat higher than that observed in the two
placebo-controlled trials involving duloxetine 60 mg
once-daily dosing [9,10]. As discussed previously, this
may be a result of the more favorable treatment outcomes
often observed in patients participating in an open-label
study. However, other confounding factors also preclude
any detailed between-study comparisons, including dif-
fering treatment periods (12 weeks in this study vs. 9
weeks in the placebo-controlled studies), somewhat
higher baseline severity of depression in the present study
(HAMD total score of 23.7 vs. 20–21 in the placebo-con-
trolled studies), and differing analytical methods (LOCF
in the current study vs. MMRM in the placebo-controlled
studies).
In summary, both safety and efficacy results from this
open-label study are supportive of those obtained from
more rigorous double-blind, placebo-controlled trials.
The cohort of 533 patients in this study was the largest
patient group to receive the recommended therapeutic
dose of 60 mg once daily in any duloxetine study to date.
Despite the limited utility of efficacy data obtained under
open-label conditions, it is hoped that the results
described here will provide clinically relevant information
for practicing clinicians, especially with regard to the
safety and tolerability of duloxetine.
A number of study limitations should be considered when
interpreting the present results. As mentioned previously,
the principal limitation is the open-label nature of the
study and the lack of placebo or active comparator treat-
ment arms. Secondly, the study was of 12 weeks duration
and therefore the results are applicable only to acute
phase treatment of MDD. Thirdly, patients received a
fixed 60 mg dose of duloxetine throughout the study,
although the option of a temporary downward titration to
30 mg QD was available at the beginning of the treatment
period. Outcomes may have differed if dosing regimens
had been optimized on an individual patient basis.
Fourthly, patients with serious or unstable medical ill-
nesses were excluded from the study, which limits the gen-
eralizability of the current results to a general population
of depressed patients.BMC Psychiatry 2007, 7:43 http://www.biomedcentral.com/1471-244X/7/43
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Conclusion
In this open-label study of over 500 patients with a diag-
nosis of MDD, duloxetine (60 mg QD) was safe and effi-
cacious in the treatment of both emotional and painful
physical symptoms of depression. Safety and tolerability
results were consistent with those observed previously in
double-blind, placebo-controlled studies.
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